GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptahem AB (XSAT:APTA) » Definitions » Common Stock

Aptahem AB (XSAT:APTA) Common Stock : kr9.03 Mil (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Aptahem AB Common Stock?

Aptahem AB's quarterly common stock stayed the same from Sep. 2023 (kr13.44 Mil) to Dec. 2023 (kr13.44 Mil) but then declined from Dec. 2023 (kr13.44 Mil) to Mar. 2024 (kr9.03 Mil).

Aptahem AB's annual common stock increased from Dec. 2021 (kr26.91 Mil) to Dec. 2022 (kr38.07 Mil) but then declined from Dec. 2022 (kr38.07 Mil) to Dec. 2023 (kr13.44 Mil).


Aptahem AB Common Stock Historical Data

The historical data trend for Aptahem AB's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptahem AB Common Stock Chart

Aptahem AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.89 14.97 26.91 38.07 13.44

Aptahem AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.07 11.73 13.44 13.44 9.03

Aptahem AB Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Aptahem AB (XSAT:APTA) Business Description

Traded in Other Exchanges
N/A
Address
Norra Vallgatan 58, Malmo, SWE, 211 22
Aptahem AB develops aptamer-based drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact in the disease process. The company's main candidate Apta-1 is developed as an emergency medicine intended to prevent the occurrence of life-threatening organ and tissue damage in patients suffering from sepsis.

Aptahem AB (XSAT:APTA) Headlines

No Headlines